Arcturus Therapeutics (ARCT) Projected to Post Quarterly Earnings on Tuesday

Arcturus Therapeutics (NASDAQ:ARCT) is expected to be releasing its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.92) per share and revenue of $14.3180 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Arcturus Therapeutics Price Performance

Shares of ARCT opened at $8.23 on Monday. The company has a market capitalization of $233.81 million, a P/E ratio of -3.35 and a beta of 2.40. Arcturus Therapeutics has a one year low of $5.85 and a one year high of $24.17. The business’s 50 day simple moving average is $7.20 and its 200-day simple moving average is $11.54.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. raised its position in shares of Arcturus Therapeutics by 97.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 23,318 shares of the biotechnology company’s stock valued at $303,000 after acquiring an additional 11,490 shares during the period. Rhumbline Advisers increased its stake in Arcturus Therapeutics by 19.8% in the second quarter. Rhumbline Advisers now owns 40,137 shares of the biotechnology company’s stock valued at $522,000 after purchasing an additional 6,636 shares in the last quarter. Alps Advisors Inc. increased its stake in Arcturus Therapeutics by 78.0% in the fourth quarter. Alps Advisors Inc. now owns 23,325 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 10,224 shares in the last quarter. nVerses Capital LLC acquired a new stake in Arcturus Therapeutics in the fourth quarter worth $140,000. Finally, CANADA LIFE ASSURANCE Co boosted its position in shares of Arcturus Therapeutics by 27.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,567 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Wall Street Analyst Weigh In

ARCT has been the subject of a number of research reports. HC Wainwright lowered their target price on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Piper Sandler lowered their price target on shares of Arcturus Therapeutics from $140.00 to $72.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Finally, Citigroup dropped their price objective on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, January 6th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.00.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.